logo
Plus   Neg
Share
Email

Pearson 2011 Statutory Pre-tax Profit Up - Quick Facts

Pearson Plc's (PSON.L,PSO) full-year 2011 statutory pre-tax profit advanced to 1.15 billion pounds from 670 million pounds in 2010, while profit attributable to equity holders of the company declining to 957 million pounds from prior year's 1.30 billion pounds.

Statutory earnings per share for the full year were 119.3 pence, considerably lower than 161.5 pence a year earlier. However, on an adjusted basis, earnings per share grew to 86.5 pence from 77.5 pence last year.

On a headline basis, sales on continuing operations totaled 5.86 billion pounds, a 4% increase from 5.66 billion pounds a year earlier. Sales, on an underlying basis, rose by 1% in 2011 versus 2010.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT